A microplate comprising: a plurality of wells arranged in a two-dimensional array, each of the wells comprising: a bottom surface, sidewalls extending from the bottom surface to form an open top; and at least two subwells in the bottom surface, the at least two subwells having sidewalls that extend below the bottom surface of the well, wherein each of the at least two subwells comprises a capture binding agent that is configured to bind to a target analyte, if present, in a sample. A sample is added to the well such that the sample fluidically contacts each of the at least two subwells such that a target analyte, if present, binds to the capture binding agent in one or more of the at least two subwells, wherein a labeled conjugate (e.g., an upconverting nanoparticle (UCNP) labeled conjugate) in the sample binds with the target analyte, if present. A label (e.g., UCNP) of the labeled conjugate is detected at one or more of the at least two subwells to thereby determine whether the target analyte is present in the sample.

The present disclosure provides a system comprising a communication interface and computer for assigning a label to the biomolecule fingerprint, wherein the label corresponds to a biological state. The present disclosure also provides a sensor arrays for detecting biomolecules and methods of use. In some embodiments, the sensor arrays are capable of determining a disease state in a subject.

Certain aspects of the present disclosure generally relate to systems and methods for determining viruses such as coronaviruses. For instance, some aspects are directed to systems and methods for determining viruses using a partitioning system. Within the partitioning system, free RNA or other nucleic acids may preferentially partition into one phase, while intact viruses may be present in the other phase or in both phases. Accordingly, in some cases, free RNA or other nucleic acids may be preferentially removed, e.g., as compared to intact RNA or other nucleic acids present within a virus. In some cases, the phase containing intact viruses can be determined to determine the infectiousness, e.g., of a sample arising from a subject. This may be useful, for example, for distinguishing subjects who are capable of spreading an infection from those who are not infectious.

Provided herein are methods and systems for the production of a nanolipoprotein particle (NLP) that includes a scaffold protein a membrane forming lipid and optionally a target protein. At least one of the scaffold protein and target protein can be provided through an IVT system. The membrane forming lipid, scaffold protein and optionally the target protein can be assembled for a time and under conditions that allow obtaining high yield NLPs, NPLs with an increased solubility, an NLP of a controlled size, and/or an NLP having a size predetermined to include a pre-selected target protein.

The present disclosure provides encoded chromophoric polymer particles that are capable of, for example, optical and/or biomolecular encoding of analytes. The present disclosure also provides suspensions comprising a plurality of encoded chromophoric polymer particles. The present disclosure also provides methods of using the encoded chromophoric polymer particles and systems for performing multiplex analysis with encoded chromophoric polymer particles.

The present invention provides a method for increasing the sensitivity of LFIAs by using palladium nanoparticles, selecting appropriate dye chemistries, and improving the timing of the development chemistry. In the presence of a palladium nanoparticle, three reagents interact with a catalytic label to form a colored dye. The three reagents include a hydrogen peroxide source, a color developer (a substituted para-phenylenediamine), and a color coupler (e.g. a napthol or a phenol). The timing of the development chemistry is improved by any combination of using a reducing agent, delaying hydrogen peroxide application by diffusion, using dissolving materials as a time delay, using serpentine flow, and separating the color coupler and the color developer on the strip.

Imaging method for a biological sample using microscopy, for example fluorescence optical microscopy, electron microscopy, or correlative microscopy, which provides to use imaging probes to obtain images in which it is possible to identify the imaging probes and/or possible molecules associated with them. The present invention also concerns the imaging probes, possibly functionalized, that can be used both in CLEM experiments and also in immunocytochemical experiments.

To provide phosphor-integrated nanoparticles for target substance detection, having improved staining performance for labeling and detecting a target protein at high accuracy. The phosphor-integrated nanoparticles for target substance detection are obtained by surface-modifying phosphor-integrated nanoparticles with a surface modification molecule. The surface modification molecule is at least one kind of surface modification molecule selected from the group consisting of a single-chain antibody containing a heavy chain variable region and an aptamer.

A construct for detecting cellular membrane potential includes a nanoparticle operable as an electron donor; a modular peptide attached to the nanoparticle, the peptide comprising a nanoparticle association domain, a motif configured to mediate peptide insertion into the plasma membrane, and at least one attachment point for an electron acceptor positioned at a controlled distance from the nanoparticle; and an electron acceptor. The nanoparticle can be a quantum dot and the electron acceptor can be C.sub.60 fullerene. Emission correlates with cellular membrane potential.

A method and system for determining the presence or absence of cancerous cells within subject tissue. The method includes: providing a material that includes a peptide component configurable in a non-binding form when disposed in a neutral pH environment, and in a binding form when disposed in an acidic pH environment, wherein the peptide component is configured to produce a first Raman spectrum when subjected to one or more predetermined wavelengths of light; administering the material to a subject tissue; interrogating the subject tissue with light; sensing the subject tissue for light emitted from the subject tissue, and producing signals representative of the sensed emitted light; analyzing the signals to determine a presence or absence of the first Raman spectrum; and determining the presence or absence of cancerous cells based on the presence or absence of the first Raman spectrum within the sensed light emitted from the subject tissue.